SCHEMBL22874683

SCHEMBL22874683

CC(C)C1CCN(C(=O)Cc2ccccc2F)CC1

nearest known ligand 0.60

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 1/20 0.52
CNR1 P21554 1/20 0.51
C3AR1 Q16581 2/20 0.50
KDM4E B2RXH2 1/20 0.46
APOBEC3A P31941 1/20 0.46
APOBEC3G Q9HC16 1/20 0.46
HPGD P15428 1/20 0.45
KMT2A Q03164 2/20 0.45
MEN1 O00255 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
EPHX2 P34913 1/20 0.44
CCR3 P51677 2/20 0.44
OPRD1 P41143 1/20 0.44
OPRK1 P41145 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13503938 0.85 CCR3 (0.54) KDM4EAPOBEC3AAPOBEC3GKMT2AMEN1
SCHEMBL22875382 0.80 L3MBTL1 (0.66) KDM4EHPGDSMN1; SMN2L3MBTL1
SCHEMBL18711458 0.79 L3MBTL1 (0.51) CNR1KDM4EKMT2AMEN1L3MBTL1
SCHEMBL22874751 0.78 SMN1; SMN2 (0.58) KMT2AMEN1SMN1; SMN2L3MBTL1
SCHEMBL22874685 0.76 GPR119 (0.53) GPR119KDM4EKMT2AMEN1EPHX2
SCHEMBL13503788 0.76 KDM4E (0.61) KDM4EKMT2AMEN1EPHX2L3MBTL1
SCHEMBL22875386 0.76 MAPT (0.50) KDM4EAPOBEC3AAPOBEC3GHPGDKMT2A
SCHEMBL8665194 0.76 L3MBTL1 (0.48) CNR1KDM4EKMT2AL3MBTL1
SCHEMBL18701998 0.75 L3MBTL1 (0.48) CNR1KDM4EKMT2AMEN1L3MBTL1
SCHEMBL2603243 0.75 KDM4E (0.50) CNR1KDM4ESMN1; SMN2EPHX2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11753397-B2 Cereblon binders for the degradation of ikaros C4 THERAPEUTICS, INC. (US) 2023-09-12 US disclosed
US-11753397-B2 Cereblon binders for the degradation of ikaros C4 THERAPEUTICS, INC. (US) 2023-09-12 US disclosed
US-20210009559-A1 CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS C4 THERAPEUTICS, INC. (US) 2021-01-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11753397-B2 Cereblon binders for the degradation of ikaros CRBN, IKZF1, IKZF3 GPR119 3820/4885CNR1 4469/4885C3AR1 2786/4885
US-20210009559-A1 CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS CRBN, IKZF1, IKZF3 GPR119 4102/4885CNR1 4032/4885C3AR1 2097/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.